Aditxt signs agreement to acquire Appili Therapeutics for $5.7M cash plus stock

Aditxt, Inc.

Acquisition for ~$5.7M cash plus ~332,876 Aditxt shares; ~$0.0467/sh + 0.002745 ADTX share per Appili share.
Assets include FDA-approved LIKMEZ, DoD-funded ATI-1701 tularemia vaccine ($14M award), and ATI-1801 topical leishmaniasis treatment.
Closing conditioned on Aditxt raising at least $20M financing by June 30, 2024; termination fee of CDN$1.25M if not met.
Transaction requires Appili shareholder vote, court approval, and NASDAQ listing of Consideration Shares.
Outstanding Appili options/warrants cashed out for additional ~$341,000 aggregate.

item 1.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Aditxt, Inc. entered into Arrangement Agreement with Appili Therapeutics, Inc. (effective 2024-04-01).

Action: entry
Agreement: merger
Counterparty: Appili Therapeutics, Inc.
Effective: 2024-04-01

Exact text from the filing

On April 1, 2024 (the “ Execution Date ”), Aditxt, Inc., a Delaware corporation (the “ Company ”), entered into an Arrangement Agreement (the “ Arrangement Agreement ”) with Adivir, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Adivir ” or the “ Buyer ”), and Appili Therapeutics, Inc., a Canadian corporation (“ Appili ”), pursuant to which, Adivir will acquire all of the issued and outstanding Class A common shares of Appili

View on SEC.gov

419 material agreements filed in the last 30 days. Browse all material agreements →

Aditxt, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-030466

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.